Purpose: To evaluate the effects of ocular biometric variables on corneal biomechanical properties.
Methods: A total of 102 eyes of 102 participants were enrolled in this cross-sectional study. The axial length (AL) was determined by an IOL master 500 and measurements of corneal biomechanical properties were performed using Corvis ST, integrated with pentacam results.
Cornea
March 2018
Purpose: To evaluate the efficacy of topical tacrolimus 0.05% as adjuvant therapy to corticosteroids in the treatment of acute endothelial rejection of a penetrating keratoplasty (PKP) graft.
Methods: Patients with the clinical diagnosis of acute endothelial rejection of a PKP graft were randomized into 2 groups-group 1: receiving topical tacrolimus 0.
Purpose: To evaluate the best piggyback intraocular lens (IOL) implantation method and the outcomes in nanophthalmos eyes and to define the postoperative structural changes.
Setting: Farabi Eye Hospital, Tehran, Iran.
Design: Prospective case series.
Purpose: To assess the pseudophakic anterior chamber depth (PP-ACD) or effective lens position (ELP) change after cataract surgery in patients with pseudoexfoliation syndrome (PEX).
Methods: Consecutive eyes with PEX and cataract underwent standard phacoemulsification and were implanted with single-piece acrylic posterior chamber intraocular lenses (IOLs). Eyes with severe PEX and with axial length (AL) greater than 24 mm or less than 22 mm were not included.
Purpose: To evaluate anterior segment optical coherence tomography (AS-OCT) in the preoperative simulation of postoperative iris-fixated phakic intraocular lens (pIOL) position in the anterior chamber.
Setting: Farabi Eye Research Center, Department of Ophthalmology, Tehran University of Medical Sciences, Tehran, Iran.
Design: Case series.
Purpose: To evaluate the efficacy of intralesional bevacizumab injection in decreasing size of pterygium.
Methods: Seventeen patients with pterygium (14 with primary and 3 with recurrent pterygium) received intralesional injections of bevacizumab (2.5 mg/0.